Option chain shows key data for Atara Biotherapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Atara Biotherapeutics.

Atara Biotherapeutics (NASDAQ:ATRA) Stock, Option Chain

Atara Biotherapeutics

Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).

Crude-oil-4-logo

Earnings

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

ATHA

ATRA

DLTR

FFIE

OGEN

WISA

Crude Oil Down 1%; Dollar Tree Shares Tumble After Downbeat Earnings

vaccine-4892048

Atara Biotherapeutics shares are trading higher by 20% Wednesday morning. The company announced a $36 million registered direct offering.

Atara Biotherapeutics (ATRA) Stock Is Up 20%: What&#39;s Going On?

xr:d:DAFlCWD77dU:2,j:2660894045622293926,t:23060609

Pre-Market Outlook

Movers

ALAB

ASAN

BTCS

CLOV

CNFR

ELAB

FCUV

GNLX

GTLB

LGMK

MSGM

SHPH

SIFY

TANH

Why GitLab Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket

Atara Biotherapeutics, Inc. - Common Stock

Atara Biotherapeutics Inc

Rodman &amp; Renshaw analyst Tony Butler initiates coverage on Atara Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) with a Buy rating and announces Price Target of $25.

Price Target

Initiation

Analyst Ratings

Rodman & Renshaw Initiates Coverage On Atara Biotherapeutics with Buy Rating, Announces Price Target of $25

WIIM

Atara Biotherapeutics shares are trading higher after the company reported better-than-expected Q3 sales results. Also, Canaccord Genuity maintained a Buy rating on the stock and raised its price target from $13 to $21.

Canaccord Genuity analyst John Newman maintains Atara Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) with a Buy and raises the price target from $13 to $21.

Canaccord Genuity Maintains Buy on Atara Biotherapeutics, Raises Price Target to $21

Atara Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) reported quarterly losses of $(2.93) per share which missed the analyst consensus estimate of $(2.50) by 17.2 percent. The company reported quarterly sales of $40.190 million which beat the analyst consensus estimate of $35.168 million by 14.28 percent. This is a 1.78K percent increase over sales of $2.138 million the same period last year.

Earnings Beats

Earnings Misses

Atara Biotherapeutics Q3 2024 GAAP EPS $(2.93) Misses $(2.50) Estimate, Sales $40.190M Beat $35.168M Estimate

ABOS

ABSI

ACNT

ACTG

AENT

AGEN

AIOT

AIRG

ALIT

ALTG

AMBC

AMPS

AMTX

APEI

AREB

ARIS

ARMN

AUTL

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AXSM

AZTA

BHIL

BLDE

BLFS

BLTE

The Beachbody Company, Inc. Class A Common Stock

BODI

BRTX

BTMD

BTTR

BWAY

BXSL

BZFD

CAMT

CART

CATX

CAVA

CBAT

CBLL

CCLD

CGEN

CHGG

CHMI

CLSD

CNNE

CRNX

CRON

CRVS

CRWS

CVAC

CXAI

DAVA

DAVE

DRCT

DYAI

EARN

EGAN

ELMD

ETON

EVCM

EVGO

EYEN

FENG

FGEN

FIHL

FLNG

FOUR

FTCI

GENI

GENK

GMGI

GOVX

GRAL

GRDN

GROV

GRPN

GRVY

Earnings Scheduled For November 12, 2024

Atara Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) is gearing up to announce its quarterly earnings on Tuesday, 2024-11-12. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Atara Biotherapeutics will report an earnings per share (EPS) of $-1.93.
Atara Biotherapeutics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Performance in Previous Earnings</h3>
The company's EPS missed by $1.54 in the last quarter, leading to a 3.22% increase in the share price on the following day.
Here's a look at Atara Biotherapeutics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.56</td>
<td>-6.50</td>
<td>-12</td>
<td>-16.5</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-3.10</td>
<td>-5.75</td>
<td>-14</td>
<td>-16.5</td>
</tr>
<tr>
<td>Price Change %</td>
<td>3.0%</td>
<td>-3.0%</td>
<td>-1.0%</td>
<td>-6.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731348105_0.png" alt="eps graph" />
<h3>Tracking Atara Biotherapeutics's Stock Performance</h3>
Shares of Atara Biotherapeutics were trading at $11.31 as of November 08. Over the last 52-week period, shares are up 41.23%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<a href="https://www.benzinga.com/quote/ATRA/earnings">To track all earnings releases for Atara Biotherapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights into Atara Biotherapeutics's Upcoming Earnings

Hyllengren's Base Salary Increased To $520,000 Annually; No Related Person Transactions Or Arrangements Involved In Promotion

Management

Atara Biotherapeutics Appoints Eric Hyllengren As Chief Operating Officer In Addition To His Role As Chief Financial Officer

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining around 0.2% on Wednesday.
The Dow traded down 0.08% to 40,906.17 while the NASDAQ rose 0.21% to 17,172.66. The S&amp;P 500 also fell, dropping, 0.03% to 5,527.51.
Check This Out:<a href="https://www.benzinga.com/trading-ideas/long-ideas/24/09/40706790/top-3-consumer-stocks-that-could-blast-off-this-quarter"> Top 3 Consumer Stocks That Could Blast Off This Quarter</a>
Leading and Lagging Sectors Utilities shares climbed by 0.6% on Wednesday.
In trading on Wednesday, energy shares fell by 0.9%.
Top Headline
Shares of Dollar Tree, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) dipped over 21% on Wednesday after the company reported worse-than-expected second-quarter 2024 earnings.
The discount variety stores chain reported an adjusted EPS of 67 cents, missing the consensus of $1.04, and down 26.4% year over year. The company reported sales of $7.38 billion, up marginally by 0.07%, missing the consensus of $7.5 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Faraday Future Intelligent Electric Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIE#NASDAQ">FFIE</a>) shares shot up 43% to $4.8986.</li>
<li>Shares of Atara Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) got a boost, surging 32% to $9.00. The company announced a $36 million registered direct offering of 758,900 shares at $8.25 per share.</li>
<li>WiSA Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WISA#NASDAQ">WISA</a>) shares were also up, gaining 69% to $2.30 after the company announced that it executed a definitive asset purchase agreement to purchase the Datavault intellectual property and information technology assets of privately held Data Vault Holdings for $210 million.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Athira Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHA#NASDAQ">ATHA</a>) shares dropped 78% to $0.6361 after the company released topline results from its Phase 2/3 LIFT-AD clinical trial of fosgonimeton for mild-to-moderate Alzheimer's disease (AD).</li>
<li>Shares of Oragenics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OGEN#NYSE">OGEN</a>) were down 45% to $0.59. Oragenics priced its $4.45 million public offering of 8,106,584 shares at $0.55 per share.</li>
<li>Psyence Biomedical Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) was down, falling 33% to $0.2482. The company announced it entered into a worldwide, exclusive royalty-bearing IP licensing agreement with PsyLabs.</li>
</ul>
Commodities In commodity news, oil traded down 1% to $69.68 while gold traded up 0.2% at $2,527.20.
Silver traded up 0.9% to $28.595 on Wednesday, while copper fell 0.3% to $4.0805.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 0.97%, Germany's DAX fell 0.83% and France's CAC 40 fell 0.98%. Spain's IBEX 35 Index fell 0.58%, while London's FTSE 100 fell 0.35%.
The S&amp;P Global UK services PMI climbed to 53.7 in August from 52.5 in the prior month. Producer prices in the Eurozone rose 0.8% month-over-month in July versus a revised 0.6% increase in June. The HCOB Eurozone composite PMI was revised lower to 51 in August versus a flash reading of 51.2.
Asia Pacific Markets
Asian markets closed lower on Wednesday, with Japan's Nikkei 225 falling 4.24%, Hong Kong's Hang Seng Index falling 1.10%, China's Shanghai Composite Index declining 0.67% and India's BSE Sensex falling 0.25%.
The HSBC India Composite PMI rose to 60.7 in August versus a flash reading of 60.5. Caixin China General Composite PMI came in unchanged at 51.2 in August.
Economics
The trade deficit in the U.S. increased to $78.8 billion in July, recording the biggest gap since June 2022, versus a gap of $73 billion in June.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40708182/wall-streets-most-accurate-analysts-weigh-in-on-3-energy-stocks-with-over-7-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Energy Stocks With Over 7% Dividend Yields</a></li>
</ul>

Atara Biotherapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) shares are trading higher by 30.7% to $8.87 Wednesday morning. The company announced a $36 million registered direct offering of 758,900 shares at <a href="https://www.benzinga.com/pressreleases/24/09/b40695909/atara-biotherapeutics-announces-36-million-registered-direct-offering">$8.25 per share.</a>
The offering, priced at a 15% premium to the company&#8217;s recent average stock price, involves the sale of 758,900 shares at $8.25 per share and 3,604,780 pre-funded warrants at $8.2499 per share. The pre-funded warrants are almost immediately exercisable.&nbsp;
The investors include Redmile Group, EcoR1 Capital, Adiumentum Capital Management and a large public biotech company. The offering is expected to close around September 5.
Additionally, Greg Ciongoli, founder of Adiumentum Capital, will join Atara&#8217;s Board of Directors. The funds will be used for working capital and general corporate purposes.
Read Also: <a href="https://www.benzinga.com/markets/equities/24/09/40696921/traders-bet-aggressively-on-rate-cuts-ahead-of-jobs-data-5-etfs-to-watch-this-week">Traders Bet Aggressively On Rate Cuts Ahead Of Jobs Data: 5 ETFs To Watch This Week</a>
<h2 class="wp-block-heading">How To Buy ATRA Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Atara Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>)'s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, ATRA has a 52-week high of $49.00 and a 52-week low of $4.96.

Atara Biotherapeutics (ATRA) Stock Is Up 20%: What's Going On?

Shares of GitLab Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTLB#NASDAQ">GTLB</a>) rose sharply in today's pre-market trading after the company reported better-than-expected second-quarter financial results and issued <a href="https://www.benzinga.com/news/earnings/24/09/40696793/gitlab-stock-climbs-on-q2-results-strong-fy-25-guidance">FY25 guidance above estimates.</a>
GitLab reported quarterly earnings of 15 cents per share, which beat the analyst consensus estimate by 50%. Quarterly revenue came in at $182.6 million, which beat the analyst consensus estimate of $176.889 million by 3.23%.
GitLab shares jumped 16.8% to $52.21 in the pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>WiSA Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WISA#NASDAQ">WISA</a>) gained 63.2% to $2.22 in pre-market trading as the company said it has executed a definitive asset purchase agreement to purchase the Datavault&#xAE; intellectual property and information technology assets of privately held Data Vault Holdings Inc.</li>
<li>Conifer Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNFR#NASDAQ">CNFR</a>) rose 39.1% to $1.60 in today's pre-market trading. Conifer Holdings shares jumped 74% on Tuesday after the company announced that it completed the sale of its insurance agency operations for a $45 million consideration. The company appointed Brian Roney As CEO.</li>
<li>LogicMark, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) gained 29.4% to $0.2618 in pre-market trading after gaining over 12% on Monday.</li>
<li>Atara Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) gained 17.2% to $7.99 in pre-market trading. The company announced a $36 million registered direct offering of 758900 shares at $8.25 per share.</li>
<li>Tantech Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TANH#NASDAQ">TANH</a>) gained 16% to $0.1613 in the pre-market trading session.</li>
<li>BTCS Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTCS#NASDAQ">BTCS</a>) gained 10% to $1.10 in pre-market trading after dipping around 15% on Tuesday.</li>
<li>Genelux Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLX#NASDAQ">GNLX</a>) rose 9.1% to $2.27 in pre-market trading after declining around 4% on Tuesday.</li>
<li>Clover Health Investments, Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>) gained 8.4% to $2.71 in pre-market trading after subsidiary Iowa Clinic signed a multi-year agreement with Counterpart Health to deploy AI technology across hundreds of Midwest providers.</li>
<li>Astera Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) gained 4% to $40.66 in pre-market trading after dipping 9% on Tuesday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Athira Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHA#NASDAQ">ATHA</a>) fell 72.7% to $0.7739 in pre-market trading after the company announced its Phase 2/3 LIFT-AD clinical trial for Fosgonimeton in mild-to-moderate Alzheimer&#8217;s disease did not meet its primary or key secondary endpoints.</li>
<li>Oragenics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OGEN#NYSE">OGEN</a>) shares fell 32.2% to $0.7254 in pre-market trading after dipping more than 15% on Tuesday. Oragenics, last month, announced the filing completion for its ONP-002 drug in anticipation of its Phase IIa clinical trail in concussed patients.</li>
<li>Focus Universal Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCUV#NASDAQ">FCUV</a>) shares fell 16.4% to $0.2530 in pre-market trading after gaining more than 12% on Tuesday.</li>
<li>Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPH#NASDAQ">SHPH</a>) shares declined 16.2% to $1.76 in pre-market trading. The company was granted #12077515 for selective histone deacetylase inhibitors.</li>
<li>Zscaler, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) fell 15.2% to $163.70 in pre-market trading following fourth-quarter earnings.</li>
<li>Asana, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASAN#NYSE">ASAN</a>) shares declined 14.6% to $11.35 in pre-market trading. Asana reported upbeat results for its second quarter but issued weak guidance for the third quarter.</li>
<li>PagerDuty, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PD#NYSE">PD</a>) fell 14.4% to $15.66 in today's pre-market trading. PagerDuty reported better-than-expected earnings for its second quarter, while sales missed estimates.</li>
<li>Elevai Labs Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELAB#NASDAQ">ELAB</a>) shares fell 11.3% to $0.2839 in pre-market trading. Elevai Labs shares gained around 20% on Tuesday after its subsidiary, Elevai Skincare, announced data results that demonstrated the potential of its proprietary Elevai Exosomes in hair restoration.</li>
<li>Motorsport Games Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSGM#NASDAQ">MSGM</a>) shares dipped 11.3% to $1.16 in pre-market trading after gaining 10% on Tuesday.</li>
<li>Sify Technologies Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIFY#NASDAQ">SIFY</a>) declined 9.6% to $0.5971 in pre-market trading after jumping around 100% on Tuesday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/09/40700996/dow-tumbles-over-600-points-nasdaq-dips-3-amid-plunge-in-nvidia-fear-index-remains-in-greed-zone">Dow Tumbles Over 600 Points, Nasdaq Dips 3% Amid Plunge In Nvidia: Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>

Atara Biotherapeutics shares are trading higher. The company announced a $36 million registered direct offering of 758900 shares at $8.25 per share.

Offerings

Atara Biotherapeutics Announces $36M Registered Direct Offering Of 758,900 Shares At $8.25/Share

HC Wainwright &amp; Co. analyst Robert Burns reiterates Atara Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) with a Neutral.

Reiteration

HC Wainwright & Co. Reiterates Neutral on Atara Biotherapeutics

Mizuho analyst Salim Syed upgrades Atara Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) from Neutral to Outperform and lowers the price target from $25 to $18.

Upgrades

Mizuho Upgrades Atara Biotherapeutics to Outperform, Lowers Price Target to $18

Canaccord Genuity analyst John Newman maintains Atara Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) with a Buy and maintains $13 price target.

Canaccord Genuity Maintains Buy on Atara Biotherapeutics, Maintains $13 Price Target

It plans to initiate ATA3219 Systemic Lupus Erythematosus trial in the&nbsp;fourth quarter, including the cohort without lymphodepletion, with initial data expected in mid-2025.

Guidance

Atara Biotherapeutics Expects Cash Runway Into 2027, Enabling Key Pipeline Readouts

Atara Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) reported quarterly losses of $(3.10) per share which missed the analyst consensus estimate of $(1.56) by 98.72 percent. The company reported quarterly sales of $28.64 million which missed the analyst consensus estimate of $39.99 million by 28.38 percent. This is a 2.89K percent increase over sales of $957.00 thousand the same period last year.

Atara Biotherapeutics Q2 2024 GAAP EPS $(3.10) Misses $(1.56) Estimate, Sales $28.64M Miss $39.99M Estimate

Goldman Sachs analyst Tommie Reerink maintains Atara Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) with a Sell and lowers the price target from $12.5 to $11.

Goldman Sachs Maintains Sell on Atara Biotherapeutics, Lowers Price Target to $11

Prescription Drug User Fee Act (PDUFA) Target Action Date of January 15, 2025
If Approved, Tab-cel Would Be First Approved Therapy in U.S. for EBV+ PTLD
BLA Acceptance Triggers $20 Million Milestone Payment from Pierre Fabre Laboratories, with Additional $60 Million Milestone if Approved by FDA

Biotech

General

Atara Biotherapeutics Receives FDA Acceptance And Priority Review Of Biologics License Application For Tabelecleucel For Treatment Of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

In a report released on August 16, Benjamin Burnett from Stifel Nicolaus maintained a Hold rating on Atara Biotherapeutics (ATRA – Research Report)...

Atara Biotherapeutics (ATRA) Gets a Hold from Stifel Nicolaus

H.C. Wainwright analyst Robert Burns has reiterated their neutral stance on ATRA stock, giving a Hold rating on August 16. Robert Burns has given h...

Atara Biotherapeutics: Hold Rating Maintained Amid Financial Shortfalls and Regulatory Uncertainties

Atara Biotherapeutics announces $36M registered direct offering

The latest announcement is out from Atara Biotherapeutics (ATRA). Atara Biotherapeutics, Inc. has announced the appointment of Mr. Gregory A. Ciong...

Atara Biotherapeutics Announces Board Appointment and Capital Raise

The latest announcement is out from Atara Biotherapeutics ( ($ATRA) ). Atara Biotherapeutics has appointed Eric Hyllengren as Chief Operating Offic...

Atara Biotherapeutics Appoints Eric Hyllengren as COO

Reports Q3 revenue $40.2M, consensus $35.2M. "With the first patient now enrolled in our Phase 1 NHL trial of ATA3219, we have taken an important s...

Atara Biotherapeutics reports Q3 EPS ($2.93), consensus ($1.93)

Atara Biotherapeutics ( ($ATRA) ) has provided an announcement. Atara Biotherapeutics is making significant strides in its immunotherapy platform, ...

Atara Biotherapeutics Advances with Strategic Partnerships

Atara Biotherapeutics GAAP EPS of -$2.93 beats by $17.16, revenue of $40.19M beats by $5.02M

Canaccord analyst John Newman raised the firm's price target on Atara Biotherapeutics (ATRA) to $21 from $13 and keeps a Buy rating on the shares. ...

Atara Biotherapeutics price target raised to $21 from $13 at Canaccord

Rodman & Renshaw analyst Tony Buter initiated coverage of Atara Biotherapeutics (ATRA) with a Buy rating and $25 price target Atara is developing T...

Atara Biotherapeutics initiated with a Buy at Rodman & Renshaw

Press Releases

Atara Biotherapeutics Announces $36 Million Registered Direct Offering

Atara Biotherapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Atara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress

Atara Biotherapeutics to Participate at the Stifel 2024 Healthcare Conference

Atara Biotherapeutics to Participate at the 7th Annual Evercore ISI HealthCONx Conference

Presenting on the Emerging Growth Conference 77 Day 1 on December 4th Register Now

Presenting on the Emerging Growth Conference 77 Day 2 on December 5th Register Now

Comments

Atara Biotherapeutics

Atara Biotherapeutics (ATRA) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga